What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.
Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Oct. 21, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced…
First results will be presented from early-stage clinical trials of BL-M07D1, antibody-drug conjugate (ADC) targeting HER2 with the payload Ed-04 Clinical progress will be presented from early-stage clinical trials of BL-B01D1, the bi-specific antibody-drug conjugate (ADC) targeting EGFR…
DUBLIN, Oct. 20, 2023 /PRNewswire/ — The “Vascular Grafts Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global vascular grafts market is poised for significant expansion, with the…
DUBLIN, Oct. 20, 2023 /PRNewswire/ — The “Fetal Monitoring – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global fetal monitoring market is expected to grow from an estimated US$3.1 billion in 2022 to approximately US$4.9 billion by…
DUBLIN, Oct. 20, 2023 /PRNewswire/ — The “Global Fluorescent in Situ Hybridization (FISH) Probe Market: (by Product, Technology, End User, Application, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)” report has been added to ResearchAndMarkets.com’s…
PEPPER PIKE, Ohio, Oct. 20, 2023 /PRNewswire/ — Prominently featured in The Inner Circle, Lawrence J. Singerman is acknowledged as a Most Trusted Healthcare Professional for his contributions to the Field of Ophthalmology. Dr. Singerman earned a Bachelor of Science degree in Psychology…
NEW YORK, Oct. 20, 2023 /PRNewswire/ — The Transcatheter Aortic Valve Replacement (TAVR) Market size is expected to increase by USD 2.34 billion, accelerating at a CAGR of 7.01% during the forecast period, according to Technavio market analysis. The report analyzes the market’s…
“The reBEAT system stands out for its unique non-blood-contacting feature, the ability to support both ventricles, and its patient-specific design. Notably, it can be implanted within minutes on a beating heart by a heart team (comprising cardiologists, surgeons, and anesthesiologists) without sutures. Its avoidance of blood-contact eliminates potential complications such as strokes and bleeding, significantly enhancing patient care and quality of life,” explained Prof. Wildhirt. He added, “Our company has worked closely with esteemed medical professionals and research teams, and has achieved remarkable progress in the field of mechanical circulatory support.”
Professor Stephan Schueler, the UK Principal Investigator from Freeman Hospital, Newcastle upon Tyne, underscored the interdisciplinary potential of reBEAT and said, “The heart team and anesthesiologists involved in this trial have been very keen to learn more about how this pulsatile device physiologically enhance cardiac performance – not only to improve overall circulation, but also the potential beneficial effects on the heart itself. Notably, reBEAT’s unique characteristic of not requiring anticoagulation is set to significantly reduce the risk of bleeding complications, making it a safer alternative for patients than incumbent technologies.”
PD Dr. Bastian Schmack, the German Principal Investigator from Hannover Medical School, shared these positive views on the outcomes from the initial implantations of reBEAT and what it implies for future treatment, “simplicity and safety of the procedure holds a very high potential to significantly reduce patient recovery time. Shorter recovery periods will alleviate pressure on healthcare facilities and enhance the overall quality of care for patients, especially those requiring mechanical cardiac support.”
Professor Arjang Ruhparwar, Chief of the Department of Cardiothoracic, Transplantation, and Vascular Surgery at Hannover Medical School, emphasized the groundbreaking nature of reBEAT noted, “the device’s unique pulsatility and non-blood-contacting nature reduce the risk of thrombosis. This has potential implications for enhancing the patient’s overall immune response, crucial for the success of treatments like heart transplantation.”
The collaborative efforts with the AdjuCor team have spanned several years, leading to crucial insights into the functionality and effectiveness of the reBEAT device. Professor Ulrich Stock, Proctor of the study and affiliated with Harefield Hospital, London, expressed enthusiasm about the successful translation of developmental improvements into the clinical settings. He also highlighted the remarkable finding of the study’s expert group of anesthesiologists, comprising Dr. Henning Pauli, PD Dr. Jan Karsten and Dr. Vikrant Pathania, regarding the ability to assess the device by echocardiography. Their expertise further emphasized the device’s potential for revolutionizing cardiac care.
“AdjuCor is dedicated to advancing medical technology, and reaching this stage in our first-in-human clinical study represents a significant milestone in our commitment towards improving patient outcomes. Our team continues to collaborate with experts in the field, driving innovation and paving the way for a future where advanced cardiac care is accessible, efficient, and safe for all,” noted Prof. Wildhirt.
26 million people world-wide suffer from heart failure. Unlike traditional treatments such as heart transplantation and mechanical blood pumps, the patented technology of AdjuCor’s reBEAT represents a revolutionary advancement in treatment of advanced heart failure patients. Its unique feature lies in its ability to be swiftly implanted around the beating heart and to support the failing heart without the complications associated with blood-contact, such as strokes and bleeding. AdjuCor’s innovative technology represents an entirely new chapter in the landscape of cardiac support care and aims to transform the lives of these patients world-wide.
About AdjuCor
AdjuCor GmbH is headquartered in Munich, Germany, and founded in 2012 by renowned cardiothoracic surgeon Prof. Stephen Wildhirt. AdjuCor’s journey from research to clinical application has been supported by the European Commission including funding from the EIC, alongside German and private investors. With over €42 million in funding and a team of 30+ experts, the company is on the brink of revolutionizing heart failure treatment.
About EIC
The European Innovation Council (EIC) is Europe’s flagship innovation program that provides funding and support for high-impact projects in the fields of technology and innovation. The EIC supports projects with the potential to create jobs, improve quality of life, and drive economic growth.
Media Contact
Dr. Hamman de Vaal, AdjuCor GmbH, 49 89262049600, [email protected], www.adjucor.com
SOURCE AdjuCor GmbH
“Immunotherapy has transformed the standard of care for cutaneous melanoma in the adjuvant and unresectable/metastatic settings, with new data suggesting a role for ICI therapy in the neoadjuvant setting as well,” said Anna C. Pavlick, DO, MBA, co-chair of the SITC Melanoma Immunotherapy Guideline Expert Panel. “We need prospective validation of predictive biomarkers to determine which patients stand to benefit from immunotherapy and which patients are more likely to develop serious immune-related adverse events.”
In addition to a lack of predictive biomarkers, other dilemmas regarding the treatment of melanoma with immunotherapy remain, such as the optimal treatment for patients whose disease has progressed through anti-PD-1 based immunotherapy (and BRAF/MEK inhibitors, if applicable), the best strategy for cure for patients with resected melanoma (adjuvant treatment versus treatment at time of recurrence), and the optimal treatment duration of immune checkpoint inhibitors.
“Immune checkpoint inhibitor therapy results in durable responses and a likely cure for many patients with advanced cutaneous melanoma,” said Ryan J. Sullivan, MD, chair of the SITC Melanoma Immunotherapy Guideline Expert Panel. “The optimal duration of immunotherapy treatment is now one of many key survivorship issues.”
The sequencing, combination, and duration of immunotherapy used to treat melanoma is highly nuanced. The Melanoma Immunotherapy Guideline Expert Panel was formed to generate evidence- and consensus-based recommendations to help clinicians select the appropriate immunotherapeutic regimens based on careful consideration of disease and patient characteristics. The guideline also includes a discussion of intratumoral immunotherapy, response monitoring, special patient populations, treatment of rare melanoma subtypes, and patient education and quality of life.
Abridged versions of the guideline highlighting key information from the publication will be available in SITC’s CPG Mobile App, along with interactive tools and tables to support clinical decision-making.
“The SITC clinical practice guidelines offer invaluable insights into the optimal use of immunotherapy for cancer treatment, backed by a critical review of available data and the extensive expertise of SITC’s distinguished panelists,” said SITC President Leisha Emens, MD, PhD. “To facilitate accessibility for busy clinicians, the SITC CPG Mobile App presents concise cancer immunotherapy recommendations, interactive tools, and algorithms in a user-friendly format.”
In addition to the guideline, SITC is also offering free live webinars and on-demand modules hosted on the SITC website focusing on topics within this guideline and providing attendees the opportunity to ask questions of expert faculty:
Dec. 1, 2023 1–2 p.m. CST – REGISTER NOW
Dec. 7, 12–1 p.m. CST – REGISTER NOW
Click here to view past SITC Cancer Immunotherapy Guidelines webinars available free and on-demand.
About SITC’s Guidelines
The SITC Cancer Immunotherapy Guidelines Program is a collection of clinical practice guidelines (CPGs) developed by multidisciplinary panels of experts who draw from practical experience as well as evidence in the published literature and clinical trial data to provide recommendations for clinicians on how and when to use immunotherapy to help improve outcomes for patients with cancer. SITC’s guidelines provide recommendations on topics including selection of appropriate immunotherapy treatments, toxicity management, biomarkers, and considerations for patient quality of life. SITC’s expanding catalogue of CPGs spans disease-state specific guidelines for several solid tumors, hematologic malignancies, and toxicity-specific guidelines to assist clinicians with the management of immune-related adverse events. You may access the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, or in the CPG Mobile App.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings, and other resources at sitcancer.org and follow us on X, LinkedIn, Facebook and YouTube.
About JITC
The Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on X @jitcancer.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected], www.sitcancer.org
SOURCE Society for Immunotherapy of Cancer
Leading not-for-profit healthcare organization in greater Los Angeles allows patients to choose a closer doctor-patient relationship ROCKVILLE CENTRE, N.Y., Oct. 20, 2023 /PRNewswire/ — Concierge Choice Physicians (CCP), the nation’s leading full-service concierge medical service…
